HER2 expression of PET imaging

RADIATION2 trials

Sponsors

Peking University Cancer Hospital & Institute

Conditions

Breast CancerHER2 Positive or Suspicious Positive Tumors

Unknown Phase

HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC

RecruitingNCT06548529

Peking University Cancer Hospital & InstituteHER2 Positive or Suspicious Positive Tumors

Start: 2024-06-01End: 2028-12-01Target: 30Updated: 2024-08-23

Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy

RecruitingNCT06909604

Peking University Cancer Hospital & InstituteBreast Cancer

Start: 2025-01-01End: 2026-12-30Target: 50Updated: 2026-05-13

Related Papers

Molecular imaging as a tool to predict patient outcomes in advanced HER2-low breast cancer on trastuzumab deruxtecan (T-DXd): The FHERAD trial.

Journal of Clinical Oncology2026-05-27